Related Experiment Video
Updated: Aug 16, 2026
10:49
Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury
Published on: September 18, 2011
[Guillain-Barre syndrome and its frontiers]
J P Azulay1, A Verschueren, S Attarian
1Service de Neurologie et Maladies Neuromusculaires, CHU la Timone, Marseille.
Revue Neurologique
|April 15, 2003
Summary
Guillain-Barré syndrome (GBS) knowledge has expanded, revealing diverse variants like axonal and sensory forms beyond the initial demyelinating definition. Current treatments include plasma exchange and IVIg for GBS management.
Area of Science:
- Neurology
- Immunology
Context:
- Guillain-Barré syndrome (GBS) definition evolved from acute inflammatory demyelinating polyneuropathy to include axonal variants.
- Epidemics of GBS in Northern China highlighted predominantly motor axonal features (AMAN) in young populations.
Purpose:
- To provide an overview of the evolving understanding of Guillain-Barré syndrome (GBS).
- To discuss the different clinical variants and their underlying pathophysiology.
- To summarize current therapeutic approaches for GBS.
Summary:
- GBS initially characterized by motor weakness and areflexia, now recognized to encompass axonal (AMAN, AMSAN) and Fisher's syndrome variants.
- Pathophysiology involves anti-GQ1b antibodies, and clinical presentations vary widely.
- Plasma exchange and IVIg are standard therapies for demyelinating GBS and likely other variants.
Impact:
- Enhanced understanding of GBS heterogeneity aids in accurate diagnosis and targeted treatment strategies.
- Recognition of diverse GBS forms improves patient outcomes and clinical management protocols.
- Ongoing research into GBS pathophysiology may lead to novel therapeutic interventions.
More Related Videos
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:22Botulism
Botulism is a life-threatening neuroparalytic condition caused by botulinum neurotoxin, which is produced by the bacterium Clostridium botulinum, a Gram-positive, spore-forming, obligate anaerobe.In adults, the toxin enters the body in different ways: in foodborne botulism, the preformed toxin is absorbed in the intestine. In wound botulism, spores grow in injured tissue and release the toxin into the blood. Infant botulism differs mechanistically from adult forms. In infants, botulism commonly...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...